CRTX - Cortexyme: The OLE Study Hold Does Not Matter February, 17 2021 04:44 PM Cortexyme Inc. The extension study of atuzaginstat has been put on hold by the FDA. The RCT is fully enrolled and no hold has been placed. The drop in price is an overreaction. For further details see: Cortexyme: The OLE Study Hold Does Not Matter